Literature DB >> 3031869

Vaccination of swine against H3N2-influenza field isolates using the human Philippines-strain.

F Haesebrouck, M Pensaert, R Wyffels.   

Abstract

Intratracheal inoculation of 2 Belgian H3N2-influenza viral strains, isolated from sick swine in the field, caused high fever, anorexia and dyspnoea in unvaccinated swine. The strains are related to the human A/Port Chalmers/1/73 (H3N2)-strain. In a limited study, 2 subunit vaccines, both derived from the human A/Philippines/2/82 (H3N2)-strain, were tested for efficacy in protecting swine against these Belgian field isolates. Vaccine A was a commercial vaccine, vaccine B an experimental vaccine. For evaluation of the efficacy of the vaccines, clinical as well as virological parameters were used. It was found that 2 spaced injections of the experimental vaccine (B) resulted in very high serum hemagglutination-inhibition (HI) titres against the Philippines-strain. Nevertheless, only partial protection was obtained, as indicated by the milder clinical signs and the decreased viral replication at challenge. One injection of the experimental vaccine (B) and 2 spaced injections of the commercial vaccine (A) did not result in any protection at challenge, even though moderate HI titres against the Philippines-strain were obtained. It was concluded that if an H3N2-strain is included in vaccines for use in swine, a strain should be selected which is identical or very closely related to the strain(s) prevalent in the swine population of the country in which the vaccine will be used.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3031869     DOI: 10.1080/01652176.1987.9694071

Source DB:  PubMed          Journal:  Vet Q        ISSN: 0165-2176            Impact factor:   3.320


  1 in total

1.  Evaluation of a protective immunity induced by an inactivated influenza H3N2 vaccine after an intratracheal challenge of pigs.

Authors:  M H Bikour; E Cornaglia; Y Elazhary
Journal:  Can J Vet Res       Date:  1996-10       Impact factor: 1.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.